News stories about Dynavax Technologies (NASDAQ:DVAX) have been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Dynavax Technologies earned a news impact score of 0.23 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.0836216335151 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
A number of equities research analysts have issued reports on DVAX shares. Cowen reiterated a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a research note on Friday, November 3rd. Cantor Fitzgerald increased their price objective on shares of Dynavax Technologies from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Thursday, November 9th. ValuEngine downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. BidaskClub downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Finally, Zacks Investment Research downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $24.83.
Shares of Dynavax Technologies (NASDAQ DVAX) opened at $17.22 on Tuesday. Dynavax Technologies has a one year low of $3.90 and a one year high of $24.45. The firm has a market cap of $1,043.77, a P/E ratio of -8.83 and a beta of 1.08.
In other news, VP David Louis Johnson sold 3,092 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $18.60, for a total value of $57,511.20. Following the sale, the vice president now directly owns 7,780 shares in the company, valued at approximately $144,708. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Robert Coffman sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $18.90, for a total transaction of $141,750.00. The disclosure for this sale can be found here. Company insiders own 2.90% of the company’s stock.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/20/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-dynavax-technologies-dvax-share-price.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.